Edgar Filing: FATE THERAPEUTICS INC - Form 4

FATE THERAPEUTICS Form 4	INC								
May 13, 2016								-	PPROVAL
UNII		URITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					N OMB Number:	3235-0287	
Section 16. Form 4 or Form 5 Filed	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Sectio of the Investment Company Act of 1940					Estimated burden hol response	Estimated average burden hours per response 0.5		
(Print or Type Responses)									
1. Name and Address of Repo Enyedy Mark J	2. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) C/O FATE THERAPEU INC.;, 3535 GENERAL COURT, SUITE 200			of Earliest T Day/Year) 2016	Fransaction			X Director Officer (gi below)		% Owner her (specify
			nendment, Date Original Ionth/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Tał	ole I - Non-	Derivative	Secu	rities A	cquired, Disposed	of, or Beneficia	ally Owned
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, in any (Month/Day/Year)		Date, if	3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or Code V Amount (D) Price			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate	e line for each cl	ass of sec	urities bene	ficially ow		rectly o	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 C S (1
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.69	05/11/2016		A	25,000	<u>(1)</u>	05/10/2026	Common Stock	25,000	

Edgar Filing: FATE THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Enyedy Mark J C/O FATE THERAPEUTICS, INC.; 3535 GENERAL ATOMICS COURT, SUI SAN DIEGO, CA 92121	TE 200	Х					
Signatures							
Cindy R. Tahl, as 05 Attorney-in-Fact	/13/2016						

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to this option shall vest and become exercisable on the earlier of (i) May 11, 2017 or (ii) the date of the 2017 Annual Meeting of Stockholders, subject to the recipient's continued service on the Issuer's Board of Directors.
- (2) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.